Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Longboard Pharmaceuticals, Inc.LBPH · Entity 85536 | Director | December 02, 2024 | December 02, 2024 |
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Director · Chief Executive Officer | January 03, 2022 | January 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Longboard Pharmaceuticals, Inc.
Report date December 02, 2024 · Filed December 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-03-10 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-02 · Disposition to issuer · Disposed 12,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-03-10 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-02 · Disposition to issuer · Disposed 14,428 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2032-05-23 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-02 · Disposition to issuer · Disposed 12,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.06 · Expires 2033-05-24 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.94 · Expires 2034-05-22 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-12-02 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Quince Therapeutics, Inc.
Report date January 03, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.39 · Expires 2032-01-02 | Direct | 440,000 |
Reported balance
After 2022-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-03 · Grant · Acquired 440,000 · Balance 440,000 F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2024 Filed Dec 2, 2024 19:29 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $18.94 | Not disclosed |
DisclosureSEC source: 0001415889-24-028028 · form4-12032024_121224.xml · derivative · entry 5 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2034-05-22 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 19:29 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $7.06 | Not disclosed |
DisclosureSEC source: 0001415889-24-028028 · form4-12032024_121224.xml · derivative · entry 4 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2033-05-24 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 19:29 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 12,367 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001415889-24-028028 · form4-12032024_121224.xml · derivative · entry 3 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,367 shares Expires 2032-05-23 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 19:29 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 14,428 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001415889-24-028028 · form4-12032024_121224.xml · derivative · entry 2 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,428 shares Expires 2031-03-10 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 19:29 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 12,367 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001415889-24-028028 · form4-12032024_121224.xml · derivative · entry 1 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,367 shares Expires 2031-03-10 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| May 23, 2024 Filed May 24, 2024 16:20 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $18.94 | $0.00 |
DisclosureSEC source: 0000950170-24-064612 · ownership.xml · derivative · entry 1 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Voting common stock · 22,500 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 23, 2024, and in any event will become fully vested on the day before the Company's next annual meeting of stockholders. Read SEC document |
| May 25, 2023 Filed May 26, 2023 16:13 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001209191-23-032513 · doc4.xml · derivative · entry 1 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Voting common stock · 12,500 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 25, 2023, and in any event will become fully vested on the day before the Company's next annual meeting of stockholders. Read SEC document |
| May 24, 2022 Filed May 31, 2022 08:29 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 12,367 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001209191-22-032735 · doc4.xml · derivative · entry 1 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Underlying: Voting common stock · 12,367 shares Expires 2032-05-23 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 24, 2022, and in any event, will become fully vested on the day before the Company's next annual meeting of stockholders. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:26 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 440,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001209191-22-001824 · doc4.xml · derivative · entry 1 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 440,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant. Read SEC document |
| November 18, 2021 Filed Nov 20, 2021 01:58 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001209191-21-065993 · doc4.xml · derivative · entry 4 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,159 Underlying: Common Stock · 60,000 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/48th of the shares on July 13, 2017, and the remaining shares vested in equal monthly installments from August 13, 2017 and ended on June 13, 2021. F4 · derivative.expiration_date: The expiration date of this option was erroneously reported as 06/0/1/2022 on the Form 3 filed on May 8, 2019. Read SEC document |
| November 18, 2021 Filed Nov 20, 2021 01:58 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 60,000 | $0.46 | $27,600.00 |
DisclosureSEC source: 0001209191-21-065993 · doc4.xml · nonDerivative · entry 1 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:51 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 183 | $36.73 | $6,721.59 |
DisclosureSEC source: 0001209191-21-032078 · doc4.xml · nonDerivative · entry 4 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 978,774 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020 and amended on December 18, 2020. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:51 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 6,315 | $35.81 | $226,140.15 |
DisclosureSEC source: 0001209191-21-032078 · doc4.xml · nonDerivative · entry 3 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 978,957 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020 and amended on December 18, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.44 to $36.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:51 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 9,918 | $34.89 | $346,039.02 |
DisclosureSEC source: 0001209191-21-032078 · doc4.xml · nonDerivative · entry 2 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 985,272 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020 and amended on December 18, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.41 to $35.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:51 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 13,584 | $33.75 | $458,460.00 |
DisclosureSEC source: 0001209191-21-032078 · doc4.xml · nonDerivative · entry 1 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 995,190 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020 and amended on December 18, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.41 to $34.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 23:06 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 400 | $36.60 | $14,640.00 |
DisclosureSEC source: 0001209191-21-022682 · doc4.xml · nonDerivative · entry 4 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,008,774 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 23:06 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 300 | $36.58 | $10,974.00 |
DisclosureSEC source: 0001209191-21-022682 · doc4.xml · nonDerivative · entry 3 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,009,174 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 23:06 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 18,089 | $35.85 | $648,490.65 |
DisclosureSEC source: 0001209191-21-022682 · doc4.xml · nonDerivative · entry 2 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,009,474 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.42 to $36.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 23:06 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 11,211 | $35.10 | $393,506.10 |
DisclosureSEC source: 0001209191-21-022682 · doc4.xml · nonDerivative · entry 1 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,027,563 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.41 to $35.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| March 11, 2021 Filed Mar 11, 2021 20:36 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 14,428 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019992 · doc4.xml · derivative · entry 2 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,428 Underlying: Voting Common Stock · 14,428 shares Expires 2031-03-10 F2 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 14 equal monthly installments commencing March 28, 2021. Read SEC document |
| March 11, 2021 Filed Mar 11, 2021 20:36 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 12,367 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019992 · doc4.xml · derivative · entry 1 Lynch Casey · CIK 0001770783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Underlying: Voting Common Stock · 12,367 shares Expires 2031-03-10 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 36 equal monthly installments commencing March 28, 2021. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 600 | $45.73 | $27,438.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 17 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,038,774 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $45.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 8,032 | $45.00 | $361,440.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 16 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,039,374 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,900 | $44.22 | $84,018.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 15 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,047,406 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.53 to $44.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,512 | $43.10 | $65,167.20 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 14 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,049,306 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.50 to $43.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 3,100 | $41.91 | $129,921.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 13 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,050,818 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.46 to $42.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 2,000 | $40.84 | $81,680.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 12 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,053,918 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.42 to $41.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 856 | $39.82 | $34,085.92 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 11 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,055,918 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $40.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,600 | $38.64 | $61,824.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 10 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,056,774 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.19 to $39.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 400 | $37.39 | $14,956.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 9 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,058,374 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 5,071 | $36.75 | $186,359.25 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 8 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,058,774 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $36.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 14,929 | $36.02 | $537,742.58 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 7 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,063,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.52 to $36.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 371 | $39.23 | $14,554.33 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 6 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,078,774 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 100 | $38.28 | $3,828.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 5 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,079,145 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 4,283 | $37.68 | $161,383.44 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 4 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,079,245 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.25 to $38.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 7,460 | $36.56 | $272,737.60 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 3 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,083,528 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.21 to $37.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 3,100 | $35.59 | $110,329.00 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 2 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,090,988 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.165 to $36.145, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 4,686 | $34.60 | $162,135.60 |
DisclosureSEC source: 0001209191-21-007540 · doc4.xml · nonDerivative · entry 1 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Zachary and Casey Lynch Living Trust dated February 24, 2009 Disclosed balance after: 1,094,088 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $35.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 00:13 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-063609 · doc4.xml · derivative · entry 2 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-12-10 F2 · derivative.exercise_date: 50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 00:13 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-063609 · doc4.xml · derivative · entry 1 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 23:08 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $54.85 | $0.00 |
DisclosureSEC source: 0001209191-20-008064 · doc4.xml · derivative · entry 1 Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.